Doctor's Doc MD

FDA Decisions & Milestones

Galleri: a favorable FDA panel vote, not approval

Under review | FDA advisory panel: September 23, 2026 | Status checked: September 30, 2026

A blood test that looks for signals from multiple cancers raises two questions: can it find a useful signal, and does acting on that signal improve outcomes for patients? Those questions are related, but they are not the same.

On September 23, an FDA advisory panel considered GRAIL's premarket approval application for Galleri. The panel voted 10-0 on safety, 6-4 on effectiveness, and 7-2, with one abstention, that the benefits outweighed the risks. These were advisory votes. They were not FDA approval. Galleri's current safety information says the test has not been FDA-cleared or approved.

What follows a cancer signal?

Galleri looks for cancer-associated methylation patterns in cell-free DNA from blood and predicts where a detected signal may have originated. The proposed FDA indication discussed by the panel was for adults aged 50 or older. A positive result requires a diagnostic workup by a qualified clinician. It is not itself a cancer diagnosis.

A negative result does not rule out cancer. Recommended screening for individual cancers still matters. Symptoms still need clinical attention, regardless of a screening result.

A regulatory milestone, with clinical questions still open

The favorable vote deserves attention. So does the evidence that tempers it. The randomized NHS-Galleri trial did not meet its primary endpoint of reducing stage III/IV cancer diagnoses in the intervention arm. A September 22 Nature Medicine paper reports this alongside its analysis of test performance. Detecting more cancers, predicting a cancer's origin and improving patient outcomes are different measures. None should stand in for the others.

Follow-up also has consequences: additional imaging, procedures, uncertainty, cost and the work required to complete the diagnostic journey. A screening program has to be judged as a whole, not only by the laboratory result.

Dr. Mohan's take

A cancer signal is the start of a diagnostic journey, not a diagnosis; the test, the follow-up and the evidence for patient benefit all have to be judged together.

The useful story here is how a new category of testing is evaluated, where the evidence is strong and where it remains incomplete. A panel vote is a milestone, not a reason to skip those distinctions.

Sources

For education only. This page does not offer personal medical advice.